glp-1 agonists with cardiovascular benefit Frontiers The conversation around GLP-1 medications

10.1038/s41419-017-0217-y [DOI] [PMC free article] [PubMed] [Google Scholar] 47.Gudbergsen H, Henriksen M, Waehrens EE, Overgaard A, Bliddal H, Christensen R, Boesen MP, Knop FKK, Astrup A, Rasmussen MU, Bartholdy C, Daugaard C, Bartels EM, Ellegaard K, Heitmann BL, Kristensen LE (2019) Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial

Conclusion: Among patients with lupus nephritis, GLP-1 receptor agonists may reduce the risk of progression to end-stage renal disease possibly due to benefits in reducing pro-inflammatory mediators

Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Int J Obes 2017;41(10):1531-1538

This made it possible to discover peptides in low abundance, including hormone precursors and processing intermediates which could not be characterised by other means at the time

With those caveats stated clearly, here is what practitioners who are using this approach are documenting